Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Hilfiker

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Organic Letters|May 25, 2002
Enantioenriched dihydropyrones from beta-lactone templatesG Greg Zipp, Mark A Hilfiker, Scott G Nelson
Journal of the American Chemical Society|November 15, 2002
A de novo enantioselective total synthesis of (-)-laulimalideScott G Nelson, Wing S Cheung, Andrew J Kassick, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Optimization of a Novel Series of TRPV4 Antagonists with In Vivo Activity in a Model of Pulmonary EdemaMark A Hilfiker, Tram H Hoang, Johan Cornil, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2009
Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonistsMark A Hilfiker, Ning Wang, Xiaoping Hou, et al.
Bioorganic & Medicinal Chemistry Letters|August 5, 2008
Aminomethylpiperazines as selective urotensin antagonistsMark A Hilfiker, Daohua Zhang, Sarah E Dowdell, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4)Carl A Brooks, Linda S Barton, David J Behm, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1Lara S Kallander, David Washburn, Mark A Hilfiker, et al.
Bioorganic & Medicinal Chemistry Letters|May 27, 2008
Development of potent and selective small-molecule human Urotensin-II antagonistsJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2008
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profilesJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
Journal of Medicinal Chemistry|January 5, 2007
Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activityRobert A Stavenger, Haifeng Cui, Sarah E Dowdell, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Organic Letters|May 25, 2002
Enantioenriched dihydropyrones from beta-lactone templatesG Greg Zipp, Mark A Hilfiker, Scott G Nelson
Journal of the American Chemical Society|November 15, 2002
A de novo enantioselective total synthesis of (-)-laulimalideScott G Nelson, Wing S Cheung, Andrew J Kassick, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Optimization of a Novel Series of TRPV4 Antagonists with In Vivo Activity in a Model of Pulmonary EdemaMark A Hilfiker, Tram H Hoang, Johan Cornil, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2009
Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonistsMark A Hilfiker, Ning Wang, Xiaoping Hou, et al.
Bioorganic & Medicinal Chemistry Letters|August 5, 2008
Aminomethylpiperazines as selective urotensin antagonistsMark A Hilfiker, Daohua Zhang, Sarah E Dowdell, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4)Carl A Brooks, Linda S Barton, David J Behm, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1Lara S Kallander, David Washburn, Mark A Hilfiker, et al.
Bioorganic & Medicinal Chemistry Letters|May 27, 2008
Development of potent and selective small-molecule human Urotensin-II antagonistsJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2008
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profilesJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
Journal of Medicinal Chemistry|January 5, 2007
Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activityRobert A Stavenger, Haifeng Cui, Sarah E Dowdell, et al.
Pageof 1